- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Nick Mitrokostas Discusses New Biosimilar Approval and the Outlook for 2020
In this episode of Not So Different, we sat down with Nick Mitrokostas, an intellectual property (IP) lawyer and partner at Goodwin's IP Litigation group, to discuss how the approval of Pfizer’s pegfilgrastim biosimilar (Nyvepria) will affect the biosimilar market and what he sees for the rest of 2020.
Recently, Pfizer announced its pegfilgrastim biosimilar (Nyvepria) was approved by the FDA, which marks the first biosimilar approval this year. Although many expected more approvals earlier in the year, experts wonder if the race to find a revolutionary treatment and vaccine for coronavirus disease 2019 (COVID-19) slowed down the approval process and biosimilars have had to take a back seat for the time being.
We sat down with Nick Mitrokostas, an intellectual property lawyer and partner at Goodwin's IP Litigation group, to discuss how this new approval will affect the biosimilar market and what he sees for the rest of 2020.
To learn more about the approval of Nyvepria, check out our article on it here.
To learn more about Goodwin Proctor LLP, visit goodwinlaw.com
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
